Tirzepatide and major adverse limb events: Insights from a multicenter real-world analysis in peripheral artery disease (PAD) and diabetes patients
Main finding · MALEsResult — go to the resultHazard ratio 0.44 95 % CI 0.33–0.59Authors' conclusion
Tirzepatide significantly lowered MALE risk in PAD patients with diabetes, suggesting a potential therapeutic role. Further prospective studies are needed to validate these findings.
Study context
- Population
- Patients with PAD and diabetes, TriNetX databasepropensity score-matched
- Participants
- 8,046 patients
- Exposure
- Tirzepatide vs controls
- Tirzepatiden = 4,023
- Controlsn = 4,023reference
- Outcome
- Major adverse limb events (MALEs)
Methodological detailspropensity score-matched, multicenter, real-world data (TriNetX database)
- Propensity score-matched
- Multicenter
- Real-world data (TriNetX database)
Main finding
MALEs
Hazard ratio
0.44
95 % CI 0.33–0.59
P < 0.001
Tirzepatidevs Controls
HR 0.44 (95 % CI 0.33–0.59); P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
All-cause mortality, acute stroke and MACE
- Tirzepatide associated with lower mortality, stroke and MACE
Acute myocardial infarction (AMI)
- AMI risk similar between groups, HR
- 0.85
- AMI risk similar between groups, P
- P = 0.29
Subgroup analyses
- Consistent findings in subgroups, except in those with prior stroke
Original publication
Tirzepatide and major adverse limb events: Insights from a multicenter real-world analysis in PAD and diabetes patients. Diabetes Res Clin Pract. Published 4 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →